N(epsilon)-(carboxymethyl)lysine (CML) (CML)

N(epsilon)-(carboxymethyl)lysine (CML) is a well-characterized advanced glycation end-product (AGE) formed by the non-enzymatic glycation and subsequent oxidative modification of lysine residues (PubChem CID 122201). It serves as a critical biomarker for oxidative stress and the cumulative damage caused by hyperglycemia, often referred to as metabolic memory (PubMed: 15506939). CML accumulates on long-lived proteins such as collagen and elastin, leading to tissue stiffening and impaired physiological function in the vasculature and kidneys (NIH: PMC2654058). Pathologically, CML acts as a ligand for the Receptor for Advanced Glycation End-products (RAGE), triggering signaling cascades that involve NF-kappaB and the production of reactive oxygen species (UniProt: Q15109). This interaction promotes chronic inflammation and is a key driver in the progression of diabetic complications, including nephropathy and retinopathy. Therapeutic approaches targeting CML include the use of glycation inhibitors like pyridoxamine and aminoguanidine, which prevent its formation from precursor molecules (PubMed: 11502824). Additionally, research has explored AGE-breakers like alagebrium to cleave the cross-links formed by CML, although clinical success has been limited. Overall, while CML is a metabolic byproduct rather than a functional protein target, it remains a primary focus for pharmacological strategies aimed at mitigating age-related and diabetic pathologies.

Other names

N6-carboxymethyllysineN(6)-carboxymethyl-L-lysine2-amino-6-(carboxymethylamino)hexanoic acidCML

Inhibition of advanced glycation end-product formation, scavenging of reactive carbonyl species, and cleavage of established protein cross-links.